Xencor Inc

자세한 내용은 Xencor Inc 회사

Xencor, Inc. is a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases. More than 20 candidates engineered with its XmAb technology are in clinical development, and three XmAb medicines are marketed by partners. Its XmAb engineering technology enables small changes to a protein structure that result in new mechanisms of therapeutic action. Its wholly owned development candidates include Vudalimab, XmAb819, XmAb808, and XmAb541. Candidates co-developed with partners include Plamotamab. Candidates advanced by partners include Xaluritamig (AMG 509), ASP2138, JNJ-9401, JNJ-1493, and Novartis XmAb undisclosed antibody candidate. Its cytokine drug candidates in clinical development consist of fbalropendekin alfa (XmAb306/RG6323), XmAb564, and XmAb662. Its other clinical-stage drug candidates consist of Obexelimab, AIMab7195 (XmAb7195), and Xpro1595. Vudalimab is a bispecific antibody that targets PD-1 and CTLA-4.

회사 정보

종목 코드 XNCR

회사 이름Xencor Inc

상장일Dec 03, 2013

CEODr. Bassil I. Dahiyat, Ph.D.

직원 수250

유형Ordinary Share

회계 연도 종료Dec 03

주소465 N. Halstead St.

도시PASADENA

증권 거래소NASDAQ Global Market Consolidated

국가United States of America

우편 번호91107

전화16263055900

웹사이트https://xencor.com/

종목 코드 XNCR

상장일Dec 03, 2013

CEODr. Bassil I. Dahiyat, Ph.D.

회사 임원

이름

이름/직위

직위

주식 보유

변동

Dr. John R. Desjarlais, Ph.D.

Executive Vice President - Research, Chief Scientific Officer

212.96K

+10.45%

Ms. Celia E. Eckert

Senior Vice President, General Counsel, Corporate Secretary

50.68K

+47.02%

Mr. Bart Jan Cornelissen

Senior Vice President, Chief Financial Officer

33.17K

-10.16%

Mr. Kurt A. Gustafson

Independent Director

14.20K

+305.17%

Mr. Todd E. Simpson

Independent Director

13.69K

--

Mr. Richard J. (Rich) Ranieri

Independent Director

13.20K

+427.04%

Dr. Kevin C. Gorman, Ph.D.

Independent Director

--

Dr. Bassil I. Dahiyat, Ph.D.

President, Chief Executive Officer, Founder and Director

--

Dr. A. Bruce Montgomery, M.D.

Lead Independent Director

--

Dr. Ellen Gwen Feigal, M.D.

Independent Director

--

이름

이름/직위

직위

주식 보유

변동

Dr. John R. Desjarlais, Ph.D.

Executive Vice President - Research, Chief Scientific Officer

212.96K

+10.45%

Ms. Celia E. Eckert

Senior Vice President, General Counsel, Corporate Secretary

50.68K

+47.02%

Mr. Bart Jan Cornelissen

Senior Vice President, Chief Financial Officer

33.17K

-10.16%

Mr. Kurt A. Gustafson

Independent Director

14.20K

+305.17%

Mr. Todd E. Simpson

Independent Director

13.69K

--

Mr. Richard J. (Rich) Ranieri

Independent Director

13.20K

+427.04%

수익 분석

통화: USD마지막 업데이트: Sun, Jul 6

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2021

FY2020

FY2019

사업별USD

이름

수익

비율

Royalties

18.23M

55.70%

Milestone

14.50M

44.30%

데이터 없음

사업별

지역별

사업별USD

이름

수익

비율

Royalties

18.23M

55.70%

Milestone

14.50M

44.30%

주식 보유 통계

마지막 업데이트: Sat, May 17

주주

주주 유형

주주

비율

BlackRock Institutional Trust Company, N.A.

15.09%

PRIMECAP Management Company

13.71%

The Vanguard Group, Inc.

12.12%

EcoR1 Capital, LLC

8.63%

T. Rowe Price Associates, Inc.

5.38%

Other

45.06%

주주

비율

BlackRock Institutional Trust Company, N.A.

15.09%

PRIMECAP Management Company

13.71%

The Vanguard Group, Inc.

12.12%

EcoR1 Capital, LLC

8.63%

T. Rowe Price Associates, Inc.

5.38%

Other

45.06%

주주 유형

주주

비율

Investment Advisor

59.58%

Investment Advisor/Hedge Fund

31.25%

Hedge Fund

15.77%

Research Firm

2.93%

Venture Capital

1.94%

Individual Investor

1.32%

Pension Fund

1.03%

Bank and Trust

0.36%

Sovereign Wealth Fund

0.25%

기관 주식 보유

마지막 업데이트: Tue, Jul 1

보고 기간

기관 수

보유 주식

비율

변동

2025Q2

437

81.46M

114.46%

-1.77M

2025Q1

459

80.70M

113.40%

-3.00M

2024Q4

454

76.54M

108.64%

-2.55M

2024Q3

455

73.66M

105.55%

+3.66M

2024Q2

436

65.64M

106.20%

-4.06M

2024Q1

431

66.91M

108.52%

-498.74K

2023Q4

420

65.39M

107.20%

-1.62M

2023Q3

417

65.14M

107.37%

-1.33M

2023Q2

422

64.91M

107.12%

-2.55M

2023Q1

418

65.89M

109.12%

+515.07K

주주 활동

이름

보유 주식

비율

변동

Chg %

날짜

BlackRock Institutional Trust Company, N.A.

10.74M

15.09%

-230.83K

-2.10%

Mar 31, 2025

PRIMECAP Management Company

9.76M

13.71%

+776.58K

+8.64%

Mar 31, 2025

The Vanguard Group, Inc.

7.88M

11.08%

-118.90K

-1.49%

Mar 31, 2025

EcoR1 Capital, LLC

6.14M

8.63%

--

Mar 31, 2025

T. Rowe Price Associates, Inc.

3.83M

5.38%

-108.25K

-2.75%

Mar 31, 2025

State Street Global Advisors (US)

3.68M

5.18%

+482.80K

+15.08%

Mar 31, 2025

BVF Partners L.P.

2.74M

3.85%

+451.38K

+19.72%

Mar 31, 2025

TCG Crossover Management, LLC

2.45M

3.45%

--

Mar 31, 2025

RTW Investments L.P.

2.40M

3.38%

--

Mar 31, 2025

Dimensional Fund Advisors, L.P.

1.74M

2.44%

+235.86K

+15.71%

Mar 31, 2025

7.900USD

Xencor Inc

7.900

개요

회사

금융